Free Trial
NASDAQ:SHPH

Shuttle Pharmaceuticals 11/13/2023 Earnings Report

Shuttle Pharmaceuticals logo
$3.52 -0.08 (-2.22%)
Closing price 08/7/2025 03:59 PM Eastern
Extended Trading
$3.52 +0.00 (+0.14%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shuttle Pharmaceuticals EPS Results

Actual EPS
-$2.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Shuttle Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shuttle Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Shuttle Pharmaceuticals' next earnings date is estimated for Tuesday, September 2, 2025, based on past reporting schedules.

Conference Call Resources

Shuttle Pharmaceuticals Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Shuttle Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (NASDAQ:SHPH), a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

View Shuttle Pharmaceuticals Profile

More Earnings Resources from MarketBeat